
AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own SEALSQ, you have to believe its post‑quantum hardware story can eventually justify a high sales multiple despite current losses and past dilution. The new US$5,000,000 Quobly agreement, coming just days after reaffirmed 2026 revenue growth guidance and the GlobalFoundries MoU, nudges the thesis from “R&D option” toward early commercial validation in quantum infrastructure, but it does not remove the near‑term execution and funding risks. Near term, the key catalysts remain converting QS7001 and the broader PQC Readiness Strategy into recurring revenue, plus proving that partnerships (Quobly, GlobalFoundries, WISeSat, automotive OEMs) translate into meaningful orders rather than small pilots. With a volatile share price and a price to sales ratio well above peers, any sign that these programs stall or slip could matter more than the Quobly contract itself.
However, investors should not ignore how much still has to go right from here. Insights from our recent valuation report point to the potential overvaluation of SEALSQ shares in the market.Explore 11 other fair value estimates on SEALSQ - why the stock might be worth less than half the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com